Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.

fool.com - 2026-07-14 08:00:00

Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.

zacks.com - 2026-07-13 19:01:06

Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.

fool.com - 2026-07-13 14:27:07

Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.

marketbeat.com - 2026-07-11 17:03:07

Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company's most important business is still performing well.

fool.com - 2026-07-10 17:00:00

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other treatment areas, and efforts have been bearing fruit.

fool.com - 2026-07-10 04:05:00

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

247wallst.com - 2026-07-09 13:29:39

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

247wallst.com - 2026-07-09 11:35:25

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, named Roundhill Memory ETF (NASDAQ:DRAM) as her final trade.

benzinga.com - 2026-07-09 07:45:15

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio.

businesswire.com - 2026-07-08 12:33:00

Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.

marketbeat.com - 2026-07-08 09:05:32

Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing.

fool.com - 2026-07-08 03:28:53

Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a late-stage candidate with more than $5 billion in combined peak-sales potential.

fool.com - 2026-07-07 23:00:00

Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day.

zacks.com - 2026-07-07 19:01:07

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast ca.

businesswire.com - 2026-07-07 16:00:00

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

247wallst.com - 2026-07-07 12:30:17

Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.

invezz.com - 2026-07-07 09:38:25

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. ("Crinetics Pharmaceuticals" or the "Company") (NASDAQ: CRNX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The investigation concerns whether the Crinetics Pharmaceuticals Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

newsfilecorp.com - 2026-07-07 09:28:00

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash).

benzinga.com - 2026-07-07 08:24:14

Vertex snaps up Crinetics, Synopsys pivots to higher-margin AI offerings, and more

fool.com - 2026-07-07 07:30:00

Shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) rose sharply in pre-market trading after the company announced it will be acquired by Vertex Pharmaceuticals (NASDAQ:VRTX).

benzinga.com - 2026-07-07 04:49:34

Vertex Pharmaceuticals Incorporated (VRTX) M&A Call Transcript

seekingalpha.com - 2026-07-07 03:32:29

Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company.

investors.com - 2026-07-06 16:49:53

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex Pharmaceuticals Inc (NASDAQ:VRTX).

benzinga.com - 2026-07-06 16:30:55

Vertex ​Pharmaceuticals ‌will buy ​Crinetics ​Pharmaceuticals ⁠for ​a total ​equity value ​of ​about $10 billion, ‌the ⁠companies said ​on ​Monday.

reuters.com - 2026-07-06 16:10:59

BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately.

businesswire.com - 2026-07-06 16:04:00

Vertex's business is growing modestly but there's much more growth potentially on the horizon. The stock's valuation has risen significantly and it's trading far higher than the S&P 500 average.

fool.com - 2026-07-06 15:10:27

Vertex Pharmaceuticals arguably dominates its market more than SpaceX does its markets. The big biotech company has multiple potentially transformative new products on the way.

fool.com - 2026-07-05 04:44:00

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

zacks.com - 2026-07-03 10:31:06

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.

zacks.com - 2026-07-02 11:46:12

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT.

businesswire.com - 2026-07-01 19:58:00

The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' gene therapy in children as ​young as two with inherited blood disorders, including ‌sickle cell disease, the first such treatment cleared for this age group.

reuters.com - 2026-07-01 18:45:07

Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis while expanding its reach into gene editing and pain management.

fool.com - 2026-07-01 11:38:42

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com - 2026-07-01 10:01:21

Vertex Pharmaceuticals Incorporated maintains a dominant, monopoly position in cystic fibrosis, driving highly predictable, recurring revenue and justifying its valuation premium. VRTX is leveraging its CF cash flows to expand into pain, hematology, and renal franchises, with promising catalysts in each area, notably Pove for IgAN. Non-CF franchises are gaining traction, with Journavx and Casgevy contributing to revenue growth; renal (Pove) is positioned to become a major driver post-2027.

seekingalpha.com - 2026-06-30 09:03:16

CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.

fool.com - 2026-06-27 06:00:03

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a +2.32% move from the preceding trading day.

zacks.com - 2026-06-26 18:50:21

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $475.12, indicating a +1.43% shift from the previous trading day.

zacks.com - 2026-06-24 19:01:07

Vertex Pharmaceuticals Incorporated's R&D success extends beyond its cystic fibrosis franchise. VRTX's Povetacicept could be approved by the FDA as early as November 30th for the treatment of an autoimmune disease called immunoglobulin A nephropathy. On the other hand, despite the high commercial expectations for Journavx and Casgevy, demand remains soft.

seekingalpha.com - 2026-06-24 09:08:33

Vertex Pharmaceuticals and Eli Lilly are both going after the non-opioid pain management market. Vertex Pharmaceuticals has a lead, but both drugmakers could be successful in this niche.

fool.com - 2026-06-20 02:00:00

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $451.63, denoting a -1.6% move from the preceding trading day.

zacks.com - 2026-06-18 18:51:16

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $458.99, denoting a +1.28% move from the preceding trading day.

zacks.com - 2026-06-17 19:00:57

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-06-17 10:02:36

The death crosses flashing on both Hershey (NYSE: HSY | HSY Price Prediction) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring.

247wallst.com - 2026-06-12 07:35:26

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $444.41, denoting a +2% move from the preceding trading day.

zacks.com - 2026-06-11 18:51:06

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent.

businesswire.com - 2026-06-11 02:01:00

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $435.76, signifying a -2.25% move from its prior day's close.

zacks.com - 2026-06-10 19:01:51

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 14:22:17